论文部分内容阅读
本文报道促肝细胞生长素（pHGF）治疗28例肝炎后肝硬化疗效，并探讨有关因素，其方法在常规综合保肝治疗的基础上用pHGF100mg～160mg加入输液中静滴，每日一次，疗程30天，并与同期未用pHGF、病情相近的肝炎后肝硬化30例作对照。结果治疗组与对照组总有效率为85.71％及66．67％。差异比较显著（X2=8．05，P＜0.01）；认为PFIGF在抑制肝脏纤维组织增生方面有一定作用，对肝炎后肝硬化治疗具有一定的价值。
This article reports the effect of hepatocyte growth hormone (pHGF) on the treatment of post-hepatitis cirrhosis in 28 cases and to explore the related factors. The method is based on routine hepatoprotective therapy with intravenous infusion of pHGF100mg ~ 160mg once daily for one week. 30 days, and with the same period without pHGF, 30 cases of similar liver cirrhosis as control. Results The total effective rate of the treatment group and the control group was 85.71% and 66.67%. (X2 = 8.05, P <0.01). It is considered that PFIGF plays a role in inhibiting the proliferation of hepatic fibrosis and has a certain value for the treatment of posthepatitic cirrhosis.